Janssen Logo. (PRNewsFoto/Janssen Pharmaceutical Companies) Facebook Twitter Pinterest × Janssen Logo. (PRNewsFoto/Janssen Pharmaceutical Companies) CORK, Ireland, December 29, 2014 /PRNewswire/ -- -- Two Companies to also Collaborate on the Further Development of Complera®, Marketed as Eviplera® in the European Union -- Janssen R&D Ireland (Janssen) announced today an amendment to its existing agreement with Gilead Sciences, Inc. (Gilead), initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. This new STR contains a combination of darunavir...
↧